Researchers in Japan have confirmed the long-term safety of induced pluripotent stem (iPS) cell therapy for the treatment of spinal cord injuries. The findings follow a period of monitoring that established the stability and safety profile of the treatment in patients.
Building on these results, the research team is now preparing to launch an investigator-initiated clinical trial. This next phase of testing is scheduled to begin as early as next year, marking a significant step toward the practical clinical application of the therapy.
In-depth summary · AI, neutral